Valuation: Opus Genetics, Inc.

Market Cap 38Cr 35Cr 32Cr 29Cr 55Cr 3.63TCr 57Cr 387.33Cr 153.59Cr 1.94TCr 144.36Cr 141.3Cr 6.15TCr P/E 2026 *
-2.93x
P/E 2027 * -5.23x
Enterprise Value 38Cr 35Cr 32Cr 29Cr 55Cr 3.63TCr 57Cr 387.33Cr 153.59Cr 1.94TCr 144.36Cr 141.3Cr 6.15TCr EV / Sales 2026 *
28.2x
EV / Sales 2027 * 31x
Free-Float
89.56%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day-1.97%
1 week-4.78%
Current month+8.45%
1 month-2.93%
3 months+10.25%
6 months-19.92%
Current year+98.01%
1 week 3.8
Extreme 3.8
4.52
1 month 3.23
Extreme 3.23
4.52
Current year 1.88
Extreme 1.88
7.07
1 year 1.7
Extreme 1.7
7.07
3 years 0.65
Extreme 0.65
7.07
5 years 0.65
Extreme 0.65
7.07
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 01/11/2023
Director of Finance/CFO 52 02/09/2025
President 60 22/10/2024
Director TitleAgeSince
Director/Board Member 77 01/11/2020
Chairman 56 01/12/2019
Director/Board Member 59 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
03/11/26 Sell

Chief Executive Officer

-28,258 0.0340%
23/10/26 Sell

Chief Operating Officer

-4,767 0.0057%
23/10/26 Sell

Chairperson

-33,189 0.0399%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-4.78%+111.70%+23.99% 38Cr
+1.26%+6.61%+40.79%+136.32% 1,28600Cr
+0.79%+3.45%+45.84%+93.52% 69TCr
+0.20%+1.28%+26.97%+113.70% 52TCr
-0.44%+3.69%+41.45%+68.91% 39TCr
+0.55%+0.70%+59.02%+44.62% 36TCr
-0.12%+0.74%+28.39%+58.54% 30TCr
+0.37%+0.37%+3.33%+37.27% 29TCr
-0.30%+1.14%+38.29%+72.46% 25TCr
+0.08%+0.71%+34.44%+124.95% 21TCr
Average +0.04%+1.39%+43.02%+77.43% 43TCr
Weighted average by Cap. +0.54%+3.26%+37.70%+96.49%

Financials

2026 *2027 *
Net sales 1.36Cr 1.23Cr 1.14Cr 1.03Cr 1.94Cr 128.42Cr 2.01Cr 14Cr 5.44Cr 69Cr 5.11Cr 5Cr 217.75Cr 1.24Cr 1.12Cr 1.04Cr 93.82L 1.77Cr 116.98Cr 1.83Cr 12Cr 4.95Cr 62Cr 4.66Cr 4.56Cr 198.35Cr
Net income -13Cr -12Cr -11Cr -9.92Cr -19Cr -1.24TCr -19Cr -132.1Cr -52Cr -660.8Cr -49Cr -48Cr -2.1TCr -7.52Cr -6.82Cr -6.31Cr -5.69Cr -11Cr -709.3Cr -11Cr -76Cr -30Cr -378.89Cr -28Cr -28Cr -1.2TCr
Net Debt - -
Projected Income Statement - Annual - Opus Genetics, Inc.
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
13/26/13 $3.980 -1.97% 7,47,424
12/26/12 $4.060 -5.80% 13,88,023
11/26/11 $4.310 +1.89% 12,06,852
10/26/10 $4.230 +0.71% 10,70,932
09/26/09 $4.200 +0.48% 11,45,763
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Opus Genetics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
3.980USD
Average target price
13.94USD
Spread / Average Target
+250.28%